Pfizer (PFE)
(Delayed Data from NYSE)
$28.58 USD
-0.22 (-0.76%)
Updated Jun 7, 2024 04:01 PM ET
After-Market: $28.55 -0.03 (-0.10%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth D Momentum D VGM
Price, Consensus and EPS Surprise
PFE 28.58 -0.22(-0.76%)
Will PFE be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for PFE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PFE
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
AbbVie (ABBV) Starts Late-Stage Study on Multiple Myeloma Drug
PFE: What are Zacks experts saying now?
Zacks Private Portfolio Services
FDA Panel to Consider Updating COVID-19 Jabs for New Virus Strains
GSK Stock Dips on Delaware Court Ruling for Zantac Litigation
Moderna (MRNA) Secures FDA Nod for mRNA-Based RSV Vaccine
Other News for PFE
Masters In Trading - Saturday, June 8
GSK wins FDA nod to expand label for RSV vaccine
Dividend Champion, Contender, And Challenger Highlights: Week Of June 9
IXJ: Growth Expected To Be Very Strong In The Next Few Years
FDA selects JN.1 variant for next COVID vaccine campaign